Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus.

Abstract	Sirolimus, a potent inhibitor of B- and T-cell activation. is a commonly used immunosuppressant after renal transplantation. Withdrawal of sirolimus from the immunosuppression regimen may reduce B-cell surveillance. We present a case of rapidly progressive central nervous system (CNS) polymorphic Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder following the withdrawal of sirolimus.
Authors	Marc Mendelson, Zunaid Barday, Roland Eastman, David Le Feuvre, Sally Candy, Hue-Tsi Wu, Charles Swanepoel
Journal	South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (S Afr Med J) Vol. 102 Issue 12 Pg. 924-6 (Aug 24 2012) ISSN: 0256-9574 [Print] South Africa
PMID	23498038 (Publication Type: Case Reports, Journal Article)
Chemical References	Immunosuppressive Agents Sirolimus
Topics	Adult Biopsy Disease Progression Graft Rejection (drug therapy) Humans Immunosuppression Therapy Immunosuppressive Agents (therapeutic use) Kidney Transplantation Lymphoproliferative Disorders (diagnosis, etiology) Male Postoperative Complications Sirolimus (therapeutic use) Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!